AU1751299A
(en)
*
|
1997-12-19 |
1999-07-12 |
Novo Nordisk A/S |
Fused 1,2,4-thiadiazine derivatives, their preparation and use
|
US6329367B1
(en)
|
1998-12-18 |
2001-12-11 |
Novo Nordisk A/S |
Fused 1,2,4-thiadiazine derivatives, their preparation and use
|
WO2000037474A1
(en)
*
|
1998-12-18 |
2000-06-29 |
Novo Nordisk A/S |
Fused 1,2,4-thiadiazine derivatives, their preparation and use
|
JP2003525211A
(ja)
*
|
1999-06-30 |
2003-08-26 |
ノボ ノルディスク アクティーゼルスカブ |
新規方法
|
WO2002000222A1
(en)
*
|
2000-06-26 |
2002-01-03 |
Novo Nordisk A/S |
Use of potassium channel agonists for the treatment of cancer
|
NZ526593A
(en)
|
2000-12-21 |
2005-02-25 |
Aventis Pharma Gmbh |
Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
|
BR0116322A
(pt)
|
2000-12-21 |
2003-10-14 |
Aventis Pharma Gmbh |
Derivados de difenilazetidinona, processo para sua preparação, medicamentos contendo esses compostos e seu emprego
|
AU2002221577A1
(en)
*
|
2000-12-21 |
2002-07-01 |
Novo-Nordisk A/S |
A new process for preparing fused 1,2,4-thiadiazine derivatives
|
DE10110747A1
(de)
|
2001-03-07 |
2002-09-12 |
Bayer Ag |
Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
|
DE10142660A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
PE20021091A1
(es)
|
2001-05-25 |
2003-02-04 |
Aventis Pharma Gmbh |
Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
|
PL366851A1
(en)
|
2001-08-22 |
2005-02-07 |
Aventis Pharma Deutschland Gmbh |
Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
|
DE10142659A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
DE10142666A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
DE10142661B4
(de)
|
2001-08-31 |
2004-06-09 |
Aventis Pharma Deutschland Gmbh |
Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
|
DE10142663B4
(de)
|
2001-08-31 |
2004-08-19 |
Aventis Pharma Deutschland Gmbh |
C2-Disubstituierte Indan-1-ol-Systeme
|
DE10142722A1
(de)
|
2001-08-31 |
2003-03-27 |
Aventis Pharma Deutschland GmbH, 65929 Frankfurt |
C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US6884812B2
(en)
|
2001-08-31 |
2005-04-26 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
|
DE10142662B4
(de)
|
2001-08-31 |
2004-07-08 |
Aventis Pharma Deutschland Gmbh |
Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
|
IL160556A0
(en)
|
2001-08-31 |
2004-07-25 |
Aventis Pharma Gmbh |
Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
|
DE10142665B4
(de)
|
2001-08-31 |
2004-05-06 |
Aventis Pharma Deutschland Gmbh |
C2-Disubstituierte Indan-1-one und ihre Derivate
|
DE10142668A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
DE10142667B4
(de)
|
2001-08-31 |
2004-06-09 |
Aventis Pharma Deutschland Gmbh |
C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel
|
US7399777B2
(en)
|
2001-08-31 |
2008-07-15 |
Sanofi-Aventis Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
|
WO2003031432A1
(en)
|
2001-10-12 |
2003-04-17 |
Novo Nordisk A/S |
Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
|
WO2003045954A1
(en)
*
|
2001-11-30 |
2003-06-05 |
Novo Nordisk A/S |
Use of selective potassium channel openers
|
WO2003045955A1
(en)
*
|
2001-11-30 |
2003-06-05 |
Novo Nordisk A/S |
Use of selective potassium channel openers
|
EP2305648A1
(en)
|
2001-12-21 |
2011-04-06 |
Novo Nordisk A/S |
Amide derivatives useful as glucokinase activators
|
US7223796B2
(en)
|
2002-04-11 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
|
US7078404B2
(en)
|
2002-04-11 |
2006-07-18 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
|
US7049341B2
(en)
|
2002-06-07 |
2006-05-23 |
Aventis Pharma Deutschland Gmbh |
N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
|
AU2003232171A1
(en)
*
|
2002-06-14 |
2003-12-31 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a beta cell resting compound
|
US7176193B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7176194B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7671047B2
(en)
|
2002-06-19 |
2010-03-02 |
Sanofi-Aventis Deutschland Gmbh |
Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
AU2003243921B2
(en)
|
2002-06-27 |
2009-05-07 |
Novo Nordisk A/S |
Aryl carbonyl derivatives as therapeutic agents
|
DE10231370B4
(de)
|
2002-07-11 |
2006-04-06 |
Sanofi-Aventis Deutschland Gmbh |
Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US7262220B2
(en)
|
2002-07-11 |
2007-08-28 |
Sanofi-Aventis Deutschland Gmbh |
Urea- and urethane-substituted acylureas, process for their preparation and their use
|
PL373329A1
(en)
|
2002-07-12 |
2005-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
|
US7141561B2
(en)
|
2002-07-25 |
2006-11-28 |
Sanofi-Aventis Deutschland Gmbh |
Substituted diaryl heterocycles, process for their preparation and their use as medicaments
|
US20040157922A1
(en)
|
2002-10-04 |
2004-08-12 |
Aventis Pharma Deutschland Gmbh |
Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
|
US7208504B2
(en)
|
2002-10-12 |
2007-04-24 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic inhibitors of hormone sensitive lipase
|
DE10258007B4
(de)
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US20040242583A1
(en)
|
2003-01-20 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
|
US7179941B2
(en)
|
2003-01-23 |
2007-02-20 |
Sanofi-Aventis Deutschland Gmbh |
Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
|
US7390814B2
(en)
|
2003-02-13 |
2008-06-24 |
Sanofi-Aventis Deutschland Gmbh |
Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
|
US7652007B2
(en)
|
2003-02-13 |
2010-01-26 |
Sanofi-Aventis Deutschland Gmbh |
Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
|
DE10306250A1
(de)
|
2003-02-14 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308351A1
(de)
|
2003-02-27 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh |
1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308352A1
(de)
|
2003-02-27 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308355A1
(de)
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308353A1
(de)
|
2003-02-27 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US7148246B2
(en)
|
2003-02-27 |
2006-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
|
US7501440B2
(en)
|
2003-03-07 |
2009-03-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
ATE467616T1
(de)
|
2003-04-11 |
2010-05-15 |
High Point Pharmaceuticals Llc |
Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
|
FR2854634B1
(fr)
*
|
2003-05-05 |
2005-07-08 |
Servier Lab |
Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
US7008957B2
(en)
|
2003-07-25 |
2006-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
AU2004275928B2
(en)
|
2003-09-30 |
2010-03-11 |
Novo Nordisk A/S |
Melanocortin receptor agonists
|
EP1694356B1
(en)
|
2003-12-09 |
2011-02-16 |
Novo Nordisk A/S |
Regulation of food preference using glp-1 agonists
|
PL1723128T3
(pl)
|
2004-01-06 |
2013-04-30 |
Novo Nordisk As |
Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy
|
US7241787B2
(en)
|
2004-01-25 |
2007-07-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
|
US7402674B2
(en)
|
2004-01-31 |
2008-07-22 |
Sanofi-Aventis Deutschland Gmbh, |
7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7498341B2
(en)
|
2004-01-31 |
2009-03-03 |
Sanofi Aventis Deutschland Gmbh |
Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7470706B2
(en)
|
2004-01-31 |
2008-12-30 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
DE102004005172A1
(de)
|
2004-02-02 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
|
DE602004004631D1
(de)
|
2004-04-01 |
2007-03-22 |
Sanofi Aventis Deutschland |
Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
|
GT200500063A
(es)
|
2004-04-01 |
2005-10-14 |
|
Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
|
EP1604988A1
(en)
|
2004-05-18 |
2005-12-14 |
Sanofi-Aventis Deutschland GmbH |
Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
|
EP2316446A1
(en)
|
2004-06-11 |
2011-05-04 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using GLP-1 agonists
|
EP1841749A1
(en)
|
2004-09-02 |
2007-10-10 |
Metabasis Therapeutics, Inc. |
Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
|
DE102004042607A1
(de)
|
2004-09-03 |
2006-03-09 |
Bayer Healthcare Ag |
Substituierte Phenylaminothiazole und ihre Verwendung
|
EP1817049B1
(en)
|
2004-11-22 |
2012-08-01 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations with a protamine salt
|
WO2006058923A1
(en)
|
2004-12-03 |
2006-06-08 |
Novo Nordisk A/S |
Heteroaromatic glucokinase activators
|
ES2435522T3
(es)
|
2005-02-02 |
2013-12-20 |
Novo Nordisk A/S |
Derivados de insulina
|
WO2006082204A1
(en)
|
2005-02-02 |
2006-08-10 |
Novo Nordisk A/S |
Insulin derivatives
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
EP2298742B1
(en)
|
2005-06-30 |
2014-01-08 |
High Point Pharmaceuticals, LLC |
phenoxy acetic acids as PPAR delta activators
|
EP2386554A1
(en)
|
2005-07-04 |
2011-11-16 |
High Point Pharmaceuticals, LLC |
Compounds active at the histamine H3 receptor
|
CN101263131B
(zh)
|
2005-07-14 |
2013-04-24 |
特兰斯特克药品公司 |
脲葡糖激酶活化剂
|
WO2007009462A2
(en)
*
|
2005-07-15 |
2007-01-25 |
Region Hovedstaden V/Glostrup Hospital |
Treatment of migraine and headaches
|
WO2007015805A1
(en)
|
2005-07-20 |
2007-02-08 |
Eli Lilly And Company |
1-amino linked compounds
|
PT1951658E
(pt)
|
2005-11-17 |
2012-11-12 |
Lilly Co Eli |
Antagonistas do receptor do glucagon, preparação e utilizações terapêuticas
|
WO2007071766A2
(en)
|
2005-12-22 |
2007-06-28 |
Transtech Pharma |
Phenoxy acetic acids as ppar delta activators
|
EP2013182B1
(en)
|
2006-03-13 |
2013-09-04 |
Kyorin Pharmaceutical Co., Ltd. |
Aminoquinolones as gsk-3 inhibitors
|
AU2007229492B2
(en)
|
2006-03-28 |
2011-11-03 |
High Point Pharmaceuticals, Llc |
Benzothiazoles having histamine H3 receptor activity
|
ATE538116T1
(de)
|
2006-05-29 |
2012-01-15 |
High Point Pharmaceuticals Llc |
3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
AU2007283113A1
(en)
|
2006-08-08 |
2008-02-14 |
Sanofi-Aventis |
Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
|
DE102006042143A1
(de)
|
2006-09-08 |
2008-03-27 |
Bayer Healthcare Aktiengesellschaft |
Neue substituierte Bipyridin-Derivate und ihre Verwendung
|
CA2669874A1
(en)
|
2006-11-15 |
2008-05-22 |
High Point Pharmaceuticals, Llc |
Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
|
DE102006056740A1
(de)
|
2006-12-01 |
2008-06-05 |
Bayer Healthcare Ag |
Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
|
DE102006056739A1
(de)
|
2006-12-01 |
2008-06-05 |
Bayer Healthcare Ag |
Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
|
US8318778B2
(en)
|
2007-01-11 |
2012-11-27 |
Novo Nordisk A/S |
Urea glucokinase activators
|
DE102007002260A1
(de)
|
2007-01-16 |
2008-07-31 |
Sanofi-Aventis |
Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
|
DE102007005045B4
(de)
|
2007-01-26 |
2008-12-18 |
Sanofi-Aventis |
Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
US20080319221A1
(en)
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
DE102007035367A1
(de)
|
2007-07-27 |
2009-01-29 |
Bayer Healthcare Ag |
Substituierte Aryloxazole und ihre Verwendung
|
DE102007036076A1
(de)
|
2007-08-01 |
2009-02-05 |
Bayer Healthcare Aktiengesellschaft |
Dipeptoid-Produgs und ihre Verwendung
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE102007042754A1
(de)
|
2007-09-07 |
2009-03-12 |
Bayer Healthcare Ag |
Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
|
ATE531721T1
(de)
|
2007-09-11 |
2011-11-15 |
Kyorin Seiyaku Kk |
Cyanoaminochinolone als gsk-3-inhibitoren
|
US8476261B2
(en)
|
2007-09-12 |
2013-07-02 |
Kyorin Pharmaceutical Co., Ltd. |
Spirocyclic aminoquinolones as GSK-3 inhibitors
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
DE102007063671A1
(de)
|
2007-11-13 |
2009-06-25 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
DE102007061763A1
(de)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Substituierte azabicyclische Verbindungen und ihre Verwendung
|
DE102007061764A1
(de)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Anellierte Cyanopyridine und ihre Verwendung
|
DE102007061756A1
(de)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung
|
DE102007061757A1
(de)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung
|
DE102008008838A1
(de)
|
2008-02-13 |
2009-08-20 |
Bayer Healthcare Ag |
Cycloalkoxy-substituierte 4-Phenyl-3,5-dicyanopyridine und ihre Verwendung
|
DE102008013587A1
(de)
|
2008-03-11 |
2009-09-17 |
Bayer Schering Pharma Aktiengesellschaft |
Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
CN101555214B
(zh)
|
2008-04-08 |
2012-07-11 |
北京嘉事联博医药科技有限公司 |
苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途
|
JP2011520997A
(ja)
|
2008-05-29 |
2011-07-21 |
バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト |
2−アルコキシ置換ジシアノピリジン類およびそれらの使用
|
UY31968A
(es)
|
2008-07-09 |
2010-01-29 |
Sanofi Aventis |
Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
|
JP2012509879A
(ja)
|
2008-11-21 |
2012-04-26 |
ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー |
アダマンチルベンズアミド化合物
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
DE102008062567A1
(de)
|
2008-12-16 |
2010-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Dipeptoid-Prodrugs und ihre Verwendung
|
DE102008062566A1
(de)
|
2008-12-16 |
2010-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Aminosäureester-Prodrugs und ihre Verwendung
|
DE102009006602A1
(de)
|
2009-01-29 |
2010-08-05 |
Bayer Schering Pharma Aktiengesellschaft |
Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
|
EP2470552B1
(en)
|
2009-08-26 |
2013-11-13 |
Sanofi |
Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
|
EP2482823A2
(en)
|
2009-10-02 |
2012-08-08 |
Sanofi |
Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases
|
WO2011104378A1
(en)
|
2010-02-26 |
2011-09-01 |
Novo Nordisk A/S |
Peptides for treatment of obesity
|
BR112012021231A2
(pt)
|
2010-02-26 |
2015-09-08 |
Basf Plant Science Co Gmbh |
método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
JP6026993B2
(ja)
|
2010-03-26 |
2016-11-16 |
ノヴォ ノルディスク アー/エス |
新規のグルカゴンアナログ
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
WO2011157827A1
(de)
|
2010-06-18 |
2011-12-22 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
EP2585055A1
(de)
|
2010-06-25 |
2013-05-01 |
Bayer Intellectual Property GmbH |
Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
|
DE102010030688A1
(de)
|
2010-06-30 |
2012-01-05 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte Dicyanopyridine und ihre Verwendung
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
US20120058983A1
(en)
|
2010-09-02 |
2012-03-08 |
Bayer Pharma Aktiengesellschaft |
Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
|
US8710050B2
(en)
|
2011-03-08 |
2014-04-29 |
Sanofi |
Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8846666B2
(en)
|
2011-03-08 |
2014-09-30 |
Sanofi |
Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
EP2683702B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8809325B2
(en)
|
2011-03-08 |
2014-08-19 |
Sanofi |
Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
|
US8895547B2
(en)
|
2011-03-08 |
2014-11-25 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
WO2012120053A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
BR112013024076A2
(pt)
|
2011-03-28 |
2016-12-06 |
Novo Nordisk As |
análogos de glucagon
|
EP2726502A1
(en)
|
2011-07-01 |
2014-05-07 |
Bayer Intellectual Property GmbH |
Relaxin fusion polypeptides and uses thereof
|
BR112014000474A2
(pt)
|
2011-07-08 |
2017-02-21 |
Bayer Ip Gmbh |
proteínas de fusão libertadoras de relaxina e suas utilizações
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
RU2610175C2
(ru)
|
2011-09-23 |
2017-02-08 |
Ново Нордиск А/С |
Новые аналоги глюкагона
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
WO2013144191A1
(de)
|
2012-03-29 |
2013-10-03 |
Bayer Intellectual Property Gmbh |
Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen
|
US9867869B2
(en)
|
2012-12-12 |
2018-01-16 |
Massachusetts Institute Of Technology |
Insulin derivatives for diabetes treatment
|
RS59124B1
(sr)
|
2013-04-18 |
2019-09-30 |
Novo Nordisk As |
Stabilni, produženi koagonisti glp-1/glukagonskih receptora za medicinsku upotrebu
|
US9931351B2
(en)
|
2013-09-04 |
2018-04-03 |
Kyoto University |
Method for improving leptin resistance
|
CR20160277A
(es)
|
2013-12-19 |
2016-10-14 |
Bayer Pharma AG |
Piperidinil tetrahidroquinolinas sustituidas
|
EP3083594A1
(de)
|
2013-12-19 |
2016-10-26 |
Bayer Pharma Aktiengesellschaft |
Substituierte bipiperidinyl-derivate als adrenorezeptor alpha 2c antagonisten
|
JOP20200052A1
(ar)
|
2013-12-19 |
2017-06-16 |
Bayer Pharma AG |
بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
|
CN106029657A
(zh)
|
2013-12-19 |
2016-10-12 |
拜耳制药股份公司 |
作为肾上腺素能受体α2C拮抗剂的取代的联哌啶基衍生物
|
JP2017525656A
(ja)
|
2014-06-04 |
2017-09-07 |
ノヴォ ノルディスク アー/エス |
医療用のglp−1/グルカゴン受容体コアゴニスト
|
EP3373936A1
(en)
|
2015-11-13 |
2018-09-19 |
Bayer Pharma Aktiengesellschaft |
4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds
|
CN111032680A
(zh)
|
2017-03-15 |
2020-04-17 |
诺和诺德股份有限公司 |
能够与黑皮质素4受体结合的双环化合物
|
US20210221867A1
(en)
|
2018-05-15 |
2021-07-22 |
Novo Nordisk A/S |
Compounds Capable of Binding to Melanocortin 4 Receptor
|
WO2020053414A1
(en)
|
2018-09-14 |
2020-03-19 |
Novo Nordisk A/S |
Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
|
WO2020165031A1
(de)
|
2019-02-15 |
2020-08-20 |
Bayer Aktiengesellschaft |
Substituierte isochinolin-piperidinylmethanon-derivate
|